newsfilter
← Latest News
GlobeNewswire·

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Data supports